Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer.

Abstract

Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network guidelines recommend two tyrosine kinase inhibitors for thyroid cancer patients who are non-responsive to iodine: sorafenib and lenvatinib. Another oral kinase inhibitor, regorafenib, is not considered standard of care treatment for differentiated thyroid cancer. The chemical structures of regorafenib and sorafenib differ by a single fluorine atom. Given the significant improvement in progression-free survival (PFS) of sorafenib compared to placebo demonstrated in the phase 3 DECISION trial, we report on a patient with iodine-refractory follicular thyroid cancer treated with regorafenib as part of a phase 1 clinical trial. A 75 year old woman was diagnosed with follicular thyroid carcinoma in 2006 and initiated on treatment with regorafenib in 2011. She has completed 76 cycles with stable disease and pulmonary metastases 34% smaller than baseline.

• Authors: Selina K Wong, Quincy S C Chu, Jennifer L Spratlin, Randeep Sangha, Alexander J B McEwan, Donald W Morrish, Diane Arndt, Gwen Sergenson, Adriaan Cleton, Funan Huang, Michael B Sawyer
• Journal: Case reports in oncology (Case Rep Oncol) 2019 Sep-Dec Vol. 12 Issue 3 Pg. 791-795 ISSN: 1662-6575 [Print] Switzerland
• PMID: 31762750 (Publication Type: Case Reports)
• Copyright: Copyright © 2019 by S. Karger AG, Basel.